Amneal Pharmaceuticals (AMRX) EBIAT: 2017-2025
Historic EBIAT for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Sep 2025 value amounting to $18.1 million.
- Amneal Pharmaceuticals' EBIAT rose 54.22% to $18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.3 million, marking a year-over-year increase of 157.71%. This contributed to the annual value of -$73.9 million for FY2024, which is 51.63% down from last year.
- Amneal Pharmaceuticals' EBIAT amounted to $18.1 million in Q3 2025, which was down 49.08% from $35.6 million recorded in Q2 2025.
- In the past 5 years, Amneal Pharmaceuticals' EBIAT registered a high of $35.6 million during Q2 2025, and its lowest value of -$242.1 million during Q2 2022.
- Over the past 3 years, Amneal Pharmaceuticals' median EBIAT value was $16.8 million (recorded in 2024), while the average stood at -$2.0 million.
- Examining YoY changes over the last 5 years, Amneal Pharmaceuticals' EBIAT showed a top increase of 428.82% in 2023 and a maximum decrease of 2,576.63% in 2023.
- Amneal Pharmaceuticals' EBIAT (Quarterly) stood at -$20.5 million in 2021, then spiked by 118.42% to $3.8 million in 2022, then plummeted by 2,576.63% to -$93.3 million in 2023, then soared by 112.78% to $11.9 million in 2024, then skyrocketed by 54.22% to $18.1 million in 2025.
- Its EBIAT was $18.1 million in Q3 2025, compared to $35.6 million in Q2 2025 and $24.6 million in Q1 2025.